A leading Egyptian pharmaceutical company has signed a deal with developers of Russian Sputnik V COVID-19 vaccine to manufacture more than 40 million doses annually in Cairo.
The Russian Direct Investment Fund, along with Egypt’s Minapharm and its Berlin-based subsidiary ProBioGen AG, said the technology transfer will begin immediately. The rollout of the vaccine is expected to commence in the third quarter of 2021.
Till date, Sputnik V has been registered in 61 countries globally covering a total population of over 3 billion people. The vaccine demonstrated efficacy of 97.6%, based on the analysis of data on the infection rate of coronavirus among those in Russia vaccinated with both components of the